Oral Terbinafine as First‑Line Therapy for Pediatric Onychomycosis

Dosing and Treatment Duration

• Weight‑based oral terbinafine dosing: 125 mg daily for children weighing 20–40 kg (typical 9‑year‑old) or 250 mg daily for >40 kg; the drug is given for 12 weeks for toenail infection and 6 weeks for fingernail infection. This regimen is recommended as the first‑line option in pediatric onychomycosis guidelines. [1][2]
• Treatment length by nail type: 6 weeks for fingernail disease and 12 weeks for toenail disease when using oral terbinafine. [1][2]

Comparative Efficacy and Recommendation Strength

• Guideline recommendation: Both terbinafine and itraconazole are listed as first‑line agents with equal strength of recommendation in pediatric onychomycosis guidelines, but terbinafine is generally preferred because of superior efficacy and tolerability. [1][2]
• Adult efficacy data: In adult studies, terbinafine achieved a 46 % long‑term mycological cure rate versus 13 % for itraconazole, with lower relapse rates (23 % vs 53 %). These data support the preference for terbinafine. [3][4]

Pre‑Treatment Requirements and Safety Considerations

• Baseline laboratory testing: Prior to initiating terbinafine, obtain baseline liver function tests (LFTs) and a complete blood count (CBC). [1][2]4
• Regulatory status: Terbinafine is not licensed for pediatric use, although it remains the preferred oral agent. [3][1][2][4]

Alternative First‑Line Option: Itraconazole Pulse Therapy

• Dosing schedule: Itraconazole 5 mg/kg per day for 1 week per month; two pulses (2 months total) for fingernail infection and three pulses (3 months total) for toenail infection. [1][2]
• Monitoring: Hepatic function monitoring is required in patients with pre‑existing liver abnormalities or when continuous therapy exceeds one month. [1][2]
• Administration advice: The drug should be taken with food and in an acidic gastric environment to optimize absorption. [1][2]

Second‑Line Oral Options

Adverse‑Effect Profile of Terbinafine

• Common: Headache and gastrointestinal upset (most frequent). 2
• Rare but serious: Taste disturbance, which can be permanent. 4
• Dermatologic: Rash, pruritus, urticaria. 3
• Potential disease exacerbation: May aggravate psoriasis or trigger a sub‑acute lupus‑like syndrome. [1][2]

Follow‑Up and Monitoring During Therapy

• Long‑term monitoring: Observe patients for at least 48 weeks from treatment initiation to detect relapse. [3][4]
• Interim assessment: Re‑evaluate clinical response at 3–6 months after starting therapy; consider additional treatment if disease persists. [3][4]

Antifungal Therapy for Onychomycosis in Children

First-Line Treatment Recommendations

• The British Journal of Dermatology recommends terbinafine and itraconazole as equally effective first-line systemic treatments for dermatophyte onychomycosis in children, with terbinafine generally preferred due to its superior efficacy and safety profile 5, 6, 7
• For children with dermatophyte onychomycosis, the dosing of terbinafine is 62.5 mg daily for those weighing less than 20 kg, 125 mg daily for those weighing 20-40 kg, and 250 mg daily for those weighing more than 40 kg 5, 6, 7
• The treatment duration for terbinafine is 6 weeks for fingernails and 12 weeks for toenails 5, 6, 7
• The British Journal of Dermatology suggests that terbinafine is unlicensed for pediatric use, requiring baseline liver function tests and complete blood count before initiation 5, 6, 7

Second-Line Treatment Options

• The British Journal of Dermatology recommends fluconazole as a second-line treatment option when terbinafine and itraconazole are contraindicated or not tolerated, with a dosing of 3-6 mg/kg once weekly 5, 6, 7
• The treatment duration for fluconazole is 12-16 weeks for fingernails and 18-26 weeks for toenails 5, 6, 7
• The British Journal of Dermatology suggests that griseofulvin can be used as a second-line treatment option, with a dosing of 10 mg/kg per day for children over 1 month 5, 6, 7

Critical Management Principles

• The British Journal of Dermatology recommends mycological confirmation before initiating therapy to avoid treating non-fungal nail dystrophies 8
• The British Journal of Dermatology suggests examining parents and siblings for onychomycosis and tinea pedis, as family transmission is common 9
• The British Journal of Dermatology recommends checking for concomitant tinea capitis and tinea pedis in the affected child 9

Treatment Success Factors

• The British Journal of Dermatology suggests that children achieve higher cure rates and faster response than adults due to thinner nail plates and faster nail growth 9
• The British Journal of Dermatology recommends monitoring for at least 48 weeks from treatment start to identify potential relapse 10

Prevention Strategies

• The British Journal of Dermatology suggests decontaminating or replacing contaminated footwear to prevent the spread of onychomycosis 10
• The British Journal of Dermatology recommends applying antifungal powders inside shoes regularly to prevent the spread of onychomycosis 10
• The British Journal of Dermatology suggests keeping nails short and clean to prevent the spread of onychomycosis 10
• The British Journal of Dermatology recommends avoiding sharing nail clippers with infected family members to prevent the spread of onychomycosis 10

Guideline Recommendations for Pediatric Fingernail Onychomycosis Treatment

First‑Line Systemic Therapy

• The British Association of Dermatologists recommends oral terbinafine as the preferred first‑line agent for fingernail onychomycosis in children, with weight‑based dosing for a 6‑week course:

  • < 20 kg → 62.5 mg daily
  • 20–40 kg → 125 mg daily
  • > 40 kg → 250 mg daily  11

• The same guideline states that terbinafine is favored over itraconazole because it provides superior efficacy and tolerability, even though both are listed as first‑line options. 11

• Comparative adult data that inform pediatric practice show long‑term mycological cure rates of approximately 46 % with terbinafine versus 13 % with itraconazole, and lower relapse rates (23 % vs 53 %). 11

Alternative First‑Line Systemic Option

• If terbinafine is contraindicated or not tolerated, pulse itraconazole (5 mg/kg per day for 1 week per month, for two monthly pulses) is recommended as an alternative first‑line regimen for fingernail disease. 11

Reasons Children Respond Better Than Adults

• The guideline explains that children achieve higher cure rates and faster responses because their nail plates are thinner, allowing better drug penetration, and because their nails grow more rapidly, facilitating quicker clearance of infection. 11

Second‑Line Systemic Options (When Both Terbinafine and Itraconazole Fail)

• Fluconazole is reserved for cases where both terbinafine and itraconazole are unsuitable. 11
• Griseofulvin is no longer recommended as a first‑line therapy because of its low efficacy and the need for extended treatment periods. 11

Topical Therapy Considerations

• The British Association of Dermatologists notes that topical agents alone are generally insufficient for pediatric fingernail onychomycosis, and there are no pediatric clinical trials demonstrating their efficacy; systemic therapy remains the preferred approach. 11

• FDA‑approved topical options for children (though not recommended as monotherapy) include:

  • Efinaconazole 10 % solution – daily application for 24–48 weeks (approved for children ≥ 6 years)
  • Tavaborole 5 % solution – approved for children ≥ 6 years
  • Ciclopirox 8 % lacquer – approved for children ≥ 12 years

Clinical Pitfalls

• Griseofulvin should not be used as a first‑line agent because it achieves only about a 30 % cure rate and requires prolonged therapy. 11

Management of Toenail Onychomycosis in Adolescents

First‑Line Oral Therapy

 < 20 kg → 62.5 mg daily
 20–40 kg → 125 mg daily
* > 40 kg → 250 mg daily

Pre‑Treatment Assessment

Alternative First‑Line Option – Itraconazole Pulse Therapy

Second‑Line Oral Options (When First‑Line Agents Fail)

Both agents are cited as second‑line alternatives with the noted limitations. 12

Adverse Effects of Terbinafine (Counseling Points)

Prevention and Recurrence Reduction